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Bariatric surgeries such as the Vertical Sleeve Gastrectomy (VSG) are invasive but provide
the most effective improvements in obesity and Type 2 diabetes. We hypothesized a
potential role for the gut hormone Fibroblast-Growth Factor 15/19 which is increased after
VSG and pharmacologically can improve energy homeostasis and glucose handling. We
generated intestinal-specific FGF15 knockout (FGF15INT-KO) mice which were maintained on
high-fat diet. FGF15INT-KO mice lost more weight after VSG as a result of increased lean tissue
loss. FGF15INT-KO mice also lost more bone density and bone marrow adipose tissue
after VSG. The effect of VSG to improve glucose tolerance was also absent in FGF15INT-KO.
VSG resulted in increased plasma bile acid levels but were considerably higher in
VSG-FGF15INT-KO mice. These data point to an important role after VSG for intestinal FGF15
to protect the organism from deleterious effects of VSG potentially by limiting the increase in
circulating bile acids.
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Obesity has become a growing epidemic, where associatedcomplications such as cardiovascular morbidity, Type 2diabetes, and insulin resistance pose major health care
challenges1. Current pharmacological treatments for obesity
include <10 FDA-approved drugs, all of which demonstrate
modest effect sizes2. Although invasive, bariatric surgery is the
most effective treatment for sustained weight loss and also
improves glycemic control better than conventional weight-loss
therapies3–5.
The gastrointestinal tract plays an important role in regulating
many of the potent metabolic effects of bariatric surgery leading
to reduced body weight and improved glucose metabolism. An
important weight-independent effect of bariatric surgery is the
alteration of enterohepatic bile acid circulation resulting in
increased plasma bile levels as well as altered bile acid composi-
tion in rodents6,7 and humans8,9. We and others have hypothe-
sized that changes in the enterohepatic metabolism play
important role in the potent metabolic effects of vertical sleeve
gastrectomy (VSG) and Roux-Y Gastric Bypass (RYGB)10,11. We
identified bile acid signaling through the nuclear ligand-activated
farnesoid X receptor (FXR) as a potential link for mediating the
beneficial effects of elevated bile acids following bariatric surgery.
We also reported that bile acids are increased after VSG and that
FXR is essential for the positive effects of bariatric surgery
on weight loss and glycemic control6,12. Unlike wild-type mice,
FXR−/− mice do not maintain body weight loss and do not have
improved glucose tolerance after VSG or after bile diversion to
the ileum12,13. These studies highlighted the importance of
enterohepatic circulation in the metabolic effects following bar-
iatric surgery.
Absorbed bile acids activate intestinal FXR and its downstream
target FGF15/19 (mouse/human ortholog, respectively). FGF15/
19 is a gut hormone expressed in ileal enterocytes of the small
intestine and is released postprandially in response to bile acid
absorption among other stimuli14–17. Once released from the
ileum, FGF15/19 enters the portal venous circulation and travels
to the liver where FGF15/19 binds to its receptor FGFR4 and
represses de novo bile acid synthesis and gallbladder filling14.
Pharmacological administration of FGF15/19 has potent effects to
reduce bile acid levels and secretion at the level of both the
liver and the gallbladder18,19. Importantly, pharmacological
administration of FGF19 reduces body weight and improves
glucose regulation in rodents20. FGF15/19 stimulates protein
and glycogen synthesis, while reducing gluconeogenesis, hepatic
triglycerides, and cholesterol18,19. FGF19 levels also rise 2–4 h
postprandially, which is considerably later than insulin and GLP-
117. These notable metabolic actions and protein engineering has
made FGF19 analogues attractive candidates for the treatment of
type 2 diabetes and hepatic lipid disorders with a number of
clinical trials under way10,21–23.
Pharmacologically elevating FGF15/19 levels in rodent models
of metabolic disease results in multiple metabolic benefits
including increased energy expenditure, reduced adiposity, and
improved lipid and glucose homeostasis24–28. FGF19 levels are
lower in patients with obesity, without a strong association to
glucose metabolism nor insulin sensitivity29–33. However, other
studies report that basal FGF19 levels are inversely correlated to
glucose metabolism or insulin sensitivity34,35 and nonalcoholic
fatty liver disease (NAFLD)36,37. Most importantly, fasting and
postprandial plasma FGF19 levels in humans22,32,33,38–40 and
ileal FGF15 expression in mice (as shown in the present studies)
increase after VSG. These data point to FGF15/19 as a potential
target to mediate VSG’s effects to produce sustained weight loss
and improved glucose tolerance. To test the hypothesis of whe-
ther FGF15 plays a role in the metabolic improvements after
bariatric surgery, we generated a novel mouse model of intestinal-
specific FGF15 knock out (VilCreERT2; Fgf15f/f) and controls,
which were maintained on a 60% high-fat diet (HFD) before and
after undergoing Sham or VSG surgery. Here we report that
intestinal-derived FGF15 is necessary to prevent excessive bile
acid increases and prevent the consequent loss in muscle and
bone mass, the improvement in peripheral blood glucose reg-
ulation, and the decrease in hepatic cholesterol after VSG. These
findings point to an important role for FGF15 in the regulation of
multiple metabolic parameters following VSG.
Results
Intestinal FGF15 expression increases and prevents muscle mass
loss after VSG in mice. Numerous reports have also shown that
plasma FGF19 levels increase after weight-loss surgeries22,32,33,38–40.
Due to the lack of commercially available and validated FGF15
assays, we were unable to measure circulating FGF15 levels after
VSG in mice41,42. However, our data show that ileal FGF15
expression increases after VSG in mice (Fig. 1a). These data point to
FGF15/19 as a potential target to mediate the effects of weight-loss
surgery.
Global ablation of FGF15 in FGF15−/− mice resulted in
impaired glucose tolerance18,19, but in our hands, these mice are
surprisingly protected against diet-induced obesity43.FGF15 is
highly expressed in the developing mouse brain44–46. Expression
of FGF15 in the adult mouse becomes limited to the distal
intestine and dorsal medial hypothalamus14,15,47. Thus, we
speculate that the total body knockouts have impaired develop-
ment of the CNS, which likely contributes to their reduced weight
gain on a HFD. These issues make it difficult to use the total body
knockout to determine critical aspects of FGF15 function in adult
animals. Therefore, we generated a FGF15 flox/flox mouse to test
specific hypotheses about the tissue-specific role of FGF15 in
metabolism after VSG. The FGF15 flox/flox mice were built using
CRISPR-Cas9 with LoxP sites flanking exon 2 of the FGF15
gene. We bred these mice to VilCreERT2 mice and administered
tamoxifen (intraperitoneal, 3 doses/150 mg/kg; Fig. 1b) to
FGF15INT-KO (VilCreERT2; FGF15 flox/flox) and Controls (6
VilCreERT2, 4 FGF15 flox/flox, and 4 FGF15 flox/+ were
combined as there were no differences in the phenotypes of these
animals; Fig. 1b).
After the studies were completed, we validated exon 2 excision
within ileal mucosa (where FGF15 is most highly expressed) in all
mice (Supplementary Fig. 1). FGF15INT-KO Sham and VSG mice
had undetectable expression of ileal FGF15, with no significant
alterations in ileal FXR expression, although there was a trend of
decreased expression in FGF15INT-KO Sham compared to Control
Sham (Supplementary Fig. 1a, b). All mice received tamoxifen at
the same time, and a week later were placed on 60% high-fat diet
(HFD; Fig. 1a). Prior to surgery, Control and FGF15INT-KO mice
had similar body weight increase in response to HFD, without
differences in food intake, fat and lean mass (Fig. 1c, d, f, g).
After 8 weeks of being on HFD, each mouse underwent either a
Sham or VSG procedure and was returned to HFD four days after
surgery. VSG removes ~80% of the stomach along the stomach
curvature (Fig. 1a). As expected, Control mice receiving VSG had
sustained weight loss compared to Control Sham mice, and that
weight loss came mostly from loss of fat mass (Fig. 1e, f). Control
VSG mice maintained their lean mass even after surgery, as we have
shown before48. FGF15INT-KO VSG mice also lost a significant
amount of weight, but 9 weeks post-surgery their body weight was
significantly lower compared to Control VSG (Fig. 1e). Although
FGF15INT-KO VSG mice lost fat mass, surprisingly they also lost a
significant amount of lean mass and this loss was significantly
greater than when compared to Control VSG and both Sham
groups (Fig. 1f, g).
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Fig. 1 Intestinal FGF15 expression increases and prevents muscle mass loss after VSG in mice. a FGF15 RNA expression in duodenum, jejunum and ileum
in control Sham and VSG mice fed 60% HFD. Intestinal mucosa was collected 15min post mixed meal gavage (n= 6 Sham and 7 VSG). b Experimental
timeline. c Body weight and d food intake before surgery. e Body weight after surgery. f Fat body mass and g lean body mass before and after surgery.
h Cumulative food intake and i energy efficiency for weeks 1–8 after surgery. j Food intake, k fecal energy and l absorbed energy during week 11 after
surgery. Animal number: Control Sham (n= 6), Control VSG (n= 8), FGF15INT-KO Sham (n= 8), FGF15INT-KO VSG (n= 5). Data are shown as means ± SEM.
Panels a, c, and d were analyzed with Student’s two-tailed t test. Panels e–l were analyzed with two-way ANOVA with Tukey’s post hoc test. *p < 0.05.
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Cumulative food intake and the average energy efficiency
(change in body weight divided by food intake) for the 8 weeks
after surgery showed that the body weight loss observed in
FGF15INT-KO VSG mice was not a result of decreased food
intake (Fig. 1h, i). This introduced the possibility that the loss
of intestinal FGF15 leads to increased malabsorption following
VSG. We measured the absorbed energy by bomb calorimetry
11 weeks after surgery. The average daily food intake was not
different between the groups (Fig. 1j). However, the fecal energy
output was reduced in FGF15INT-KO VSG mice compared
to Control VSG and FGF15INT-KO Sham mice (Fig. 1k).
Given that all mice were on the same diet, FGF15INT-KO VSG
mice had increased their absorption of calories from ingested
food (Fig. 1l). Thus, the additional weight and lean mass
loss in FGF15INT-KO VSG was not secondary to nutrient
malabsorption.
Loss in muscle mass is accompanied by decreased strength
and skeletal muscle fiber size in FGF15INT-KO VSG mice.
Previous data has shown that exogenous administration or
genetic overexpression of FGF19 decreases body weight and
adiposity20,24–28, but prevents muscle mass wasting by enlar-
ging muscle fiber size and protecting muscle from atrophy49. In
addition to significant loss of muscle mass in FGF15INT-KO
VSG mice (Fig. 1g), we observed a trend of decreased grip
strength (9 weeks post-surgery) and soleus muscle fiber size
in these mice (Supplementary Fig. 2a, b). Moreover, a dis-
tribution analysis of the fiber size showed that FGF15INT-KO
VSG mice have a rightward shift towards an increased number
of smaller and a lower number of larger soleus fibers (Supple-
mentary Fig. 2c).
To further examine the atrophy-related pathways in soleus
muscle, we measured circulating Myostatin (GDF8) and Activin A
levels and the soleus muscle expression of their downstream
targets, muscle-specific E3 ubiquitin ligases Atrogin 1 and MuRF1.
We did not observe any differences in the plasma Myostatin and
Activin A levels, nor the RNA expression of Atrogin 1 (encoded
by Fbxo32) and MuRF1 (encoded by Trim63) in soleus muscle
(Supplementary Fig. 2d–g). Next, we examined plasma levels of
IGF1 and FGF21 as anti and pro-atrophy mediators in skeletal
muscle. Twelve weeks after surgery postprandial plasma levels of
IGF1 were decreased in FGF15INT-KO VSG mice compared to
Control VSG (Supplementary Fig. 2h). Studies have indicated that
FGF21 levels increase with fasting and FGF21 is necessary for the
fasting-induced muscle mass and force loss50. FGF15INT-KO VSG
mice had increased plasma levels of FGF21 compared to Control
VSG and FGF15INT-KO Sham mice (Supplementary Fig. 2i). In
addition, there was a significant negative correlation between
muscle mass and plasma FGF21 levels (Supplementary Fig. 2j).
Circulating amino acid levels 6-weeks post-surgery were not
different among the groups (Supplementary Fig. 2k).
FGF15INT-KO VSG mice did not show differences in small
bowel biometry (Supplementary Fig. 3a–c). The large bowel
weight was significantly less in FGF15INT-KO VSG compared to
FGF15INT-KO Sham mice (Supplementary Fig. 3d). However,
there was also a trend toward decreased large bowel weight in
Control VSG compared to Control Sham mice, suggesting that
decrease in large bowel weight could be related to decreased body
weight of the VSG groups (Supplementary Fig. 3d)51. The ratio of
large bowel weight/length was significantly reduced in both VSG
groups compared to Control Sham but was not significantly
different compared to FGF15INT-KO Sham mice (Supplementary
Fig. 3f). Further analysis of ileum cross-sections showed no
differences in villi height, crypt depth or the ratio of villi height/
crypt depth (Supplementary Fig. 3g–i).
Intestinal-derived FGF15 partially preserves bone and bone
marrow adipose tissue (BMAT) loss following VSG. Previous
studies in our lab have shown that loss of bone and BMAT fol-
lowing VSG is independent of body weight and diet52. In the
current study, VSG caused a precipitous loss of trabecular and
cortical bone loss in FGF15INT-KO mice. Specifically, FGF15INT-KO
VSG mice had decreased trabecular bone volume fraction (Tb. BV/
TV), trabecular bone mineral density (Tb. BMD), and trabecular
connective density (Conn. Dens) (Fig. 2a–d). Although the thick-
ness of the trabecular bone (Tb. Th) was not altered, the trabecular
number (Tb. N) was decreased, while the spacing between trabe-
culae was increased (Tb. Sp) in FGF15INT-KO VSG mice (Fig. 2e–g).
Cortical thickness (Ct. Th), bone area (Ct. BA/TA), and bone
mineral density (Ct. BMD) were reduced by VSG and further
decreased by lack of intestinal-derived FGF15 (Fig. 2h–k).
Consistent with our previous studies, both “regulated” bone
marrow adipose tissue, BMAT (rBMAT) in proximal tibia and
“constitutive” BMAT (cBMAT) in distal tibia were decreased by
VSG (representative images Fig. 2m, n)52,53. Interestingly, loss of
intestinal FGF15 caused a baseline reduction of rBMAT in
proximal tibia ranging from growth plate (GP) to tibia/fibula
junction (T/F J), with nearly complete depletion after VSG
(Fig. 2m, o, p). Although the distal tibial cBMAT of Sham mice
was unaffected by loss of intestinal FGF15, this BMAT depot was
more thoroughly depleted in FGF15INT-KO VSG mice compared
to Control VSG mice (Fig. 2n, q).
Loss of intestinal FGF15 increases circulating fibroblast growth
factor 23 (FGF23) and erythropoietin (EPO) levels after VSG.
Fibroblast growth factor 23 (FGF23), the third member
of the endocrine FGFs in addition to FGF15/19 and FGF21, is a
bone-derived hormone that regulates mineral homeostasis and
consequently bone mineral density54. Plasma FGF23 levels were
elevated almost 20,000-fold in FGF15INT-KO VSG mice (Fig. 3a).
Plasma phosphate and 25 (OH) vitamin D levels were unaffected
(Fig. 3b, c). To investigate the cause for increased plasma FGF23
levels, we measured circulating erythropoietin (EPO), a known
regulator of FGF23 and bone loss55,56. EPO was also increased by
15,000-fold in FGF15INT-KO VSG mice (Fig. 3d). Increased plasma
FGF23 and EPO levels are often observed in anemia. Hemoglobin
levels were decreased in FGF15INT-KO VSG compared to
FGF15INT-KO Sham mice (Fig. 3e). Plasma ferritin levels were
unaffected (Fig. 3f). Consistent with high levels of EPO, heart to
body weight ratio (Fig. 3g) was increased in FGF15INT-KO VSG
mice. Moreover, H&E stains in liver sections showed zonal injury
pattern (Fig. 3h). Zone 3 around the central hepatic veins appeared
paler compared to zones 1 and 2 (Fig. 3h). These patterns are
consistent with relative hypoxia, possibly secondary to anemia. The
expression of hypoxia-inducible factor 2 alpha (Hif2α) and its
target genes were upregulated in the duodenum following VSG and
independent of genotype, specifically those genes transcribing the
iron transporters divalent metal transporter Dmt1 (encoded by
Slc11a2), duodenal cytochrome B Dcytb (encoded by Cybrd1), and
Ferroportin (encoded by Slc401a1) (Fig. 3i). Duodenal expression
of hepcidin (Hamp) was not altered by VSG or lack of gut-derived
FGF15 expression (Fig. 3i). Lastly, iron content in cecal contents
was not different between the groups but showed a trend of
increased levels in both VSG groups (Fig. 3j).
Loss of intestinal FGF15 increases circulating total GLP-1
levels and increases gastric emptying after VSG. Four-hour
fasted blood glucose concentrations were not different among any
of the four groups, but insulin concentrations and HOMA-IR
were lower in FGF15INT-KO VSG compared to FGF15INT-KO
Sham (Fig. 4a–c). As expected, we saw improvements in glucose
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tolerance in Control VSG compared to Control Sham mice six-
and nine-weeks post-surgery (Fig. 4d, e). To our surprise, there
was no difference in glucose tolerance between FGF15INT-KO
VSG and FGF15INT-KO Sham mice (Fig. 4d, e).
Next, we challenged mice with a mixed meal for the assessment
of postprandial glucose excursion, insulin, and GLP-1 response.
Acetaminophen, which is rapidly absorbed once it leaves the
stomach was added to the mixed meal to assess gastric emptying
rate. FGF15INT-KO Sham mice had a similar glucose excursion
curve, but decreased gastric emptying rate compared to Control
Sham mice (Fig. 4f, g). Both VSG groups responded to the mixed
meal with similar glucose excursion curves (Fig. 4f), significantly
higher than their Sham controls as a result of increased gastric
emptying rate (Fig. 4g). Despite similar glucose excursion,
FGF15INT-KO VSG mice showed significantly higher gastric
emptying rate (indicated by the greater plasma acetaminophen
levels) compared to Control VSG mice (Fig. 4g). Basal and
postprandial insulin levels were increased in both VSG groups
compared to Sham controls (Fig. 4h). Interestingly, basal and
postprandial total GLP-1 levels were significantly higher in
FGF15INT-KO VSG mice compared to all other groups (Fig. 4i).
Loss of intestinal FGF15 results in aberrant hepatic lipid and
glycogen metabolism following VSG. FGF15INT-KO VSG had
increased liver to body weight ratio (Fig. 5a). Assessment of
glycogen stores revealed that FGF15INT-KO VSG have decreased
liver glycogen and a trend toward higher skeletal muscle
(tibialis anterior) glycogen content (Supplementary Fig. 4a, b).
Postprandial plasma alanine aminotransferase (ALT) levels, a
predictor of liver injury, and plasma cholesterol levels trended to
be reduced in both VSG groups compared to Sham controls
(Fig. 5b, c), without changes in plasma-free fatty acids or plasma
triglycerides (Fig. 5d, e).
Fig. 2 Intestinal-derived FGF15 partially preserves bone and bone marrow adipose tissue (BMAT) loss following VSG. a 3D images of trabecular bone,
scale bars 500 μm. b Trabecular bone volume fraction (Tb. BV/TV), c trabecular bone mineral density (Tb. BMD), d trabecular bone connective density
(Conn. Des) and e trabecular number (Tb. N), f thickness of the trabecular bone (Tb. Th), g spacing between trabeculae (Tb. Sp). h 3D images of mid-
cortical bone, scale bars 500 μm. i Thickness of the cortical bone (Ct. Th). j Cortical bone area (Ct. BA/TA) and k cortical bone mineral density (Ct. BMD).
l Tibial BMAT was visualized by osmium staining. m, n Representative sections from proximal and distal tibiae were stained with H&E and are shown at
×100 magnification, scale bars 200 μm. l Tibial BMAT was quantified relative to total bone volume after osmium staining within the indicated regions as
shown in (o) proximal Tibia (①-②), p growth plate (G/P) to tibia/fibula junction (T/F J) (①-③), q distal tibia is T/F J to distal end (③-④). Animal number:
Control Sham (n= 5), Control VSG (n= 8), FGF15INT-KO Sham (n= 7), FGF15INT-KO VSG (n= 5). Data are shown as means ± SEM. *p < 0.05 (two-way
ANOVA with Tukey’s post hoc test).
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Fig. 3 Loss of intestinal FGF15 increases circulating fibroblast growth factor 23 (FGF23) and erythropoietin (EPO) levels after VSG. Plasma levels of
a FGF23, b phosphate, c 25(OH) vitamin D, d erythropoietin, e hemoglobin and f ferritin. g Heart to body weight ratio. h H&E stain of liver sections, CV=
central vein, PV= portal vein, Zones 1–3, scale bars 100 μm. i RNA expression of Dmt1, Dcytb, Hamp, Slc401a1 (Fpn) and Hif2α in duodenum. j Iron levels in
cecal contents. Animal number for (a–f) and (i, j): Control Sham (n= 5), Control VSG (n= 8), FGF15INT-KO Sham (n= 8), FGF15INT-KO VSG (n= 5).
Animal number for g: Control Sham (n= 6), Control VSG (n= 8), FGF15INT-KO Sham (n= 8), FGF15INT-KO VSG (n= 5). Data are shown as means ± SEM.
*p < 0.05 (two-way ANOVA with Tukey’s post hoc test).
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Analysis of hepatic lipids revealed an increased cholesterol and
esterified cholesterol levels in FGF15INT-KO VSG mice (Fig. 5f, g).
Hepatic triacylglycerols were decreased in Control VSG com-
pared to Control Sham mice, but remained at similar levels
between FGF15INT-KO Sham and FGF15INT-KO VSG mice
(Fig. 5h). There was a trend toward decreased hepatic free
fatty acids in both VSG groups compared to Sham controls
(Fig. 5i). Surprisingly, the cholesterol synthesis rate-limiting
gene, 3-hydroxy-3-methyl-glutaryl-glutaryl-coenzyme A reductase,
Hmg-CoA reductase (Hmcgr), was upregulated in FGF15INT-KO
Sham compared to Control Sham mice, but reduced after VSG in
FGF15INT-KO VSG mice (Fig. 5j). Next, we measured the
Fig. 4 FGF15INT-KO mice remain glucose intolerant despite significant body weight loss after VSG. a Fasting (4 h) blood glucose, b fasting (4 h) insulin
levels and c HOMA-IR after surgery. d Intraperitoneal glucose tolerance test (ipGTT; 2 g/kg) performed 6-weeks post-surgery and Area Under the Curve
(AUC). e Intraperitoneal glucose tolerance test (ipGTT; 2 g/kg) performed 9 weeks post-surgery and Area Under the Curve (AUC). fMixed meal tolerance test
(MMTT) performed 10 weeks post-surgery. g Gastric emptying rate measured by acetaminophen levels at 15min post mixed meal. h Insulin levels at baseline
(4 h fast) and 15min post mixed meal. i Total GLP-1 levels at baseline (4 h fast) and 15min post mixed meal. Animal number (a–f) and (h, i): Control Sham (n=
6), Control VSG (n= 8), FGF15INT-KO Sham (n= 8), FGF15INT-KO VSG (n= 5). Animal number g: Control Sham (n= 6), Control VSG (n= 7), FGF15INT-KO
Sham (n= 8), FGF15INT-KO VSG (n= 5). Data are shown as means ± SEM. *p < 0.05 (two-way ANOVA with Tukey’s post hoc test).
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Fig. 5 Loss of intestinal FGF15 results in aberrant hepatic lipid metabolism following VSG. a Liver weight normalized to body weight. b Alanine
aminotransferase (ALT) plasma levels. c Plasma cholesterol. d Plasma-free fatty acids (FFA) and e Plasma triglycerides (postprandial, 12 weeks post-
surgery). f Total hepatic cholesterol. g Hepatic esterified cholesterol. h Hepatic triglycerides. i Hepatic free fatty acids. Hepatic RNA expression of
cholesterol synthesis gene j. Hmcgr and cholesterol export genes k. Abcg5 and l. Abcg8. Animal number for (a–i) and (k, l): Control Sham (n= 5), Control
VSG (n= 8), FGF15INT-KO Sham (n= 8), FGF15INT-KO VSG (n= 5). Animal number for j: Control Sham (n= 5), Control VSG (n= 8), FGF15INT-KO Sham
(n= 7), FGF15INT-KO VSG (n= 5). Data are shown as means ± SEM. *p < 0.05 (two-way ANOVA with Tukey’s post hoc test).
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expression in hepatic cholesterol efflux pump-ATP-binding
cassette, sub-family G, members 5 and 8 (Abcg5 and Abcg8)
and found that their expression was decreased in FGF15INT-KO
VSG mice (Fig. 5k, l). These data suggest that despite decreased
cholesterol synthesis, there is attenuated cholesterol export
leading to elevated liver cholesterol content in FGF15INT-KO
VSG mice.
The hepatic expression of FXR was similar in Control and
FGF15INT-KO mice (Supplementary Fig. 5a). We did see a trend
of decreased expression of FXR in both VSG groups compared
to their respective Sham groups (Supplementary Fig. 5a). FXR
target small heterodimer partner, SHP, was not significantly
different, but showed a trend for decreased expression in both
VSG groups. (Supplementary Fig. 5b). Fatty acid oxidation and
lipid metabolism genes fatty acid synthase (FAS) and peroxi-
some proliferator-activated receptor alpha (PPAR alpha)
were decreased in FGF15INT-KO VSG mice compared to
FGF15INT-KO Sham controls (Supplementary Fig. 5c, d).
Although not significant, there was a trend of decreased
expression of these genes in Control VSG compared to Control
Sham mice (Supplementary Fig. 5c, d). PPAR alpha target gene,
Carnitine palmitoyltransferase 1A (Cpt1a) essential for con-
verting long-chain fatty acids into energy (lipogenesis), showed
a trend toward decreased expression after VSG in FGF15INT-KO
but not Control mice (Supplementary Fig. 5e). Interestingly,
cluster of differentiation 36 (CD36), a cell surface protein that
imports fatty acids, was increased in FGF15INT-KO VSG
compared to Control VSG mice (Supplementary Fig. 5f).
Intestinal FGF15 regulates enterohepatic bile acid metabolism
following VSG. FGF15 is expressed in ileal enterocytes of the
small intestine and released postprandially in response to bile acid
absorption. Consistent with this role to inhibit bile acid pro-
duction, plasma and cecal content concentrations of bile acids are
higher in mice lacking intestinal FGF15 (Fig. 6a, b). Moreover,
plasma bile acid composition revealed higher levels of TCA
(taurocholate), CDCA (chenodeoxycholate), DCA (Deox-
ycholate), TDCA (taurodeoxycholate), and TCDCA (Fig. 6d).
VSG has been shown to alter both the concentration and com-
position of bile acids. Therefore, we assessed the role that FGF15
might play in the effect of VSG to alter bile acids. Control VSG
mice had a trend of increased plasma bile acid levels, with higher
levels of TαMCA (tauro-α-muricholate)/ TβMCA (tauro-β-
muricholate), TCA, DCA, and TDCA levels (Fig. 6d, Supple-
mentary Fig. 6). FGF15INT-KO VSG mice had much higher
plasma bile acid levels, but normal cecum content of bile acid
levels when compared to Control VSG and FGF15INT-KO Sham
mice (Fig. 6a, b). FGF15INT-KO VSG mice also had higher plasma
TαMCA/TβMCA levels (similar to Control VSG), but also high
levels of TCA, CDCA, DCA, TDCA, CA (cholate) (Fig. 6D,
Supplementary Fig. 6). The levels of hydrophobic bile acids
(GCA/glycocholate, CA/cholate, CDCA/chenodeoxycholate,
DCA/deoxycholate, LCA/lithocholic acid) in plasma were
increased by more than two-fold in FGF15INT-KO VSG compared
to Control VSG mice (Fig. 6e, Supplementary Fig. 6). Hepatic
total bile acid levels were not different but showed a trend of
decreased levels in both VSG groups (Fig. 6c). The ratios of
cholesterol to bile acids in plasma, liver, and cecal content showed
that lack of gut-derived FGF15 after VSG drives a system for
increased bile acids in plasma and increased cholesterol in the
liver (Supplementary Fig. 7a–c). Not surprisingly, lack of intest-
inal FGF15 resulted in higher expression of the bile acid synthesis
gene Cyp7a1 in FGF15INT-KO Sham compared to Control Sham
mice (Fig. 6f). However, despite the fact that FGF15INT-KO VSG
mice lack intestinal FGF15 and have increased plasma bile acid
levels, their expression of hepatic bile acid synthesis genes cho-
lesterol 7a-hydroxylase (Cyp7a1), sterol 12-alpha-hydroxylase
(Cyp8b1), and sterol 27-hydroxylase (Cyp27a1) were decreased
(Fig. 6f–h).
Next, we measured the expression of hepatic and ileal bile acid
uptake transporters. The expression of Slc10a1 (coding for liver
bile acid transporter Ntcp) and Oatp4 was decreased in
FGF15INT-KO VSG mice (Fig. 6i, j). We did not see differences
in the expression of bile acid transporter Slc10a2 (coding for
apical sodium-dependent bile acid transporter, Asbt) in the ileum
(Fig. 6k). These data suggest that bile acid uptake by liver is
reduced in FGF15INT-KO VSG mice, potentially contributing to
the increased plasma bile acid levels.
Intestinal FGF15 modulates microbiota in cecal content.
Changes in gut microbiota composition are considered a potential
contributor to the metabolic benefits of bariatric surgery57–59. We
investigated whether intestinal FGF15 modulates shifts in the
microbial communities by VSG. To determine the effects of
FGF15 on VSG-induced gut microbiota alteration, we performed
16S ribosomal RNA (rRNA) gene sequencing on cecal content
samples collected 12 weeks after surgery (collected at the time of
sacrifice). Chao1 and Shannon index were used to estimate with-
in sample richness and diversity, respectively. The former
represents the total number of microbes present in one single
sample, while the latter accounts for both richness and evenness
of the microbes. We did not see significant changes in richness
(Chao1 index) and diversity (Shannon index) (Fig. 7a, b). How-
ever, there was a trend toward increased richness in both VSG
groups compared to their respective Sham controls. In addition,
we observed a trend of decreased cecal diversity in FGF15INT-KO
Sham compared to Control Sham mice (Fig. 7b).
Linear discriminant analysis (LDA) effect size (LEfSe) analysis
showed taxonomic differences in the microbiota composition of
the cecal content between Control Sham and FGF15INT-KO Sham
groups (Fig. 7c). Firmicutes and Bacteroidetes are the most
abundant phyla in fecal microbiota. The relative proportion of
Firmicutes and Bacteroidetes has been reported to be affected
differently by obesity and high-fat feeding Firmicutes at the
phylum level, Erysipelotrichales at order level, and Allobaculum
and Ruminococcus at the family level showed a trend of decreased
abundance in FGF15INT-KO Sham compared to Control Sham
(Supplementary Fig. 8b, e, h, i). However, Lachnospiraceae at the
family level and Bacteroides at the genus level were increased in
FGF15INT-KO Sham compared to Control Sham (Supplementary
Fig. 8f, g).
LDA effect size (LEfSe) analysis showed taxonomic differ-
ences in the microbiota composition of the cecal content
between Sham and VSG in both genotype groups (Fig. 7d, e).
To further define bacteria characteristic of enrichment of Sham
and VSG in each genotype, we also performed a random forest
model. Lactobacillus species have been suggested to confer
beneficial effects in a broad spectrum60,61. At the genus level,
Lactobacillus, with an importance score of 0.301 determined by
the decrease in the classification accuracy when it was ignored,
was identified as the top-ranked discriminator for the Control
VSG compared to Control Sham gut microbiota. On the other
hand, Enterococcus genus was identified as the top discrimi-
nator for FGF15INT-KO VSG vs. FGF15INT-KO Sham gut
microbiota, with Lactobacillus genus having an importance
score of 0.088. (Fig. 7f, g).
Discussion
Increased circulating bile acids are one of the hallmarks of bar-
iatric surgery, and our group and others have identified bile acid
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Fig. 6 Intestinal FGF15 regulates enterohepatic bile acid metabolism following VSG. a Total plasma bile acid levels. b Cecal contents total bile acid levels.
c. Hepatic total bile acids. d Plasma bile acid composition. e Hydrophobic plasma bile acid levels. Hepatic RNA expression of bile acid synthesis genes.
f Cyp7a1, g Cyp8b1 and h Cyp27a1. Hepatic RNA expression of bile acid uptake genes i Slc10a1 (coding for Ntcp) and j Oatp4. k Ileum RNA expression of bile
acid uptake gene Slc10a2 (coding for Asbt). Animal number for (b), (c), (f–j): Control Sham (n= 5), Control VSG (n= 8), FGF15INT-KO Sham (n= 8),
FGF15INT-KO VSG (n= 5). Animal number for (a), (d), (e): Control Sham (n= 5), Control VSG (n= 7), FGF15INT-KO Sham (n= 6), FGF15INT-KO VSG (n=
5). Animal number for k: Control Sham (n= 5), Control VSG (n= 7), FGF15INT-KO Sham (n= 8), FGF15INT-KO VSG (n= 5). Data are shown as means ±
SEM. *p < 0.05 (two-way ANOVA with Tukey’s post hoc test).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-24914-y
10 NATURE COMMUNICATIONS |         (2021) 12:4768 | https://doi.org/10.1038/s41467-021-24914-y | www.nature.com/naturecommunications
signaling through FXR as a molecular link mediating the bene-
ficial metabolic effects of elevated bile acids following VSG12,13.
Secretion of FGF15/19 is a key response to FXR activation.
Consistent with human data that show increased circulating levels
of FGF19 after bariatric surgery22,32,33,38–40, VSG in mice upre-
gulates FGF15 expression in the ileum (Fig. 1). Here we
demonstrate that intestinal FGF15 is necessary for many of the
metabolic, morphologic, and microbiome responses to VSG.
Fig. 7 Intestinal FGF15 modulates microbiota in cecal content. a Chao1 abundance and b Shannon index diversity of the gut microbiota in the cecal contents.
LEfSex analysis depicting nodes within the bacterial taxonomic hierarchy that are enriched in cecal microbiota from c Control Sham versus FGF15INT-KO Sham
and d Control Sham versus VSG and e FGF15INT-KO Sham versus VSG. Diagrams generated by LEfSe indicating differences at phylum, order, class, family, and
genus levels between the two groups. f Top-ranked taxa at genus level identified by random forest analysis according to their ability to discriminate the
microbiota of Sham and VSGmice per genotype in decreasing order of discriminatory importance. A comparison of the abundance of markers in VSG relative to
Sham counterparts in each genotype. g. Differences in relative abundance of taxa at genus level. Animal number Control Sham (n= 6), Control VSG (n= 7),
FGF15INT-KO Sham (n= 7), FGF15INT-KO VSG (n= 5). Data in (a, b) are shown as means ± SEM. *p < 0.05 (two-way ANOVA with Tukey’s post hoc test).
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To study the specific role of intestinal FGF15 in the response to
VSG, we built a mouse model that allowed for specific deletion of
FGF15 from the intestine in the adult animal (see Fig. 1 and
“Methods”). Compared to control animals, these mice have
similar body weight, body fat, food intake, and glucose regulation
when challenged on a HFD. These data argue that intestinally
derived FGF15 is not necessary for physiologic regulation of
energy balance and glucose levels in diet-induced obese animals
without bariatric surgery. It is important to note that these
findings differ from gut-specific ablation of FXR, findings that
were hypothesized to be dependent upon FXR’s downstream
target FGF1562,63. Gut-specific FXR knock out mice (VilCre; FXR
flox/flox) are metabolically fit and resistant to HFD-induced
metabolic disease63,64. However, ablation of FXR in adult mice
(VilCreERT2; FXR flox/flox) does not lead to resistance to HFD-
induced obesity, similar to our FGF15INT-KO Sham mice13. It is
also important to note that we previously found that unlike wild-
type mice, FXR−/− mice did not maintain body weight loss
and did not have improved glucose tolerance after VSG
and while maintained on HFD12. A caveat of these studies is that
FXR−/− mice are resistant to HFD-induced obesity and
glucose intolerance, and therefore, the window for improvement
in these parameters is smaller65. This is also the case for total
body FGF15−/− mice, as we also recently reported43. The key
point is that it is likely that FXR and FGF15’s role in metabolic
regulation is different in various tissues and it is also sensitive to
ablation during development versus in the adult mouse. These are
critical components for interpreting the role bile acid metabolism
plays following bariatric surgery and a major rationale for why we
built a model that would allow for tissue-specific deletion of
FGF15 in the adult mouse.
Once released from the ileum, FGF15 enters the portal venous
circulation and travels to the liver where FGF15 binds to
its receptor FGFR4 and represses de novo bile acid synthesis
through suppression of the rate-limiting enzyme cholesterol 7a-
hydroxylase (Cyp7a1)14. Therefore, bile acids and FGF15/19
inhibit further bile acid synthesis and facilitate communication
between the small intestine and liver. As predicted, the lack of
FGF15 resulted in increased plasma bile acids and cecal bile acid
content in FGF15INT-KO Sham mice (Fig. 6). After VSG, plasma
bile acids were further increased in FGF15INT-KO VSG mice, but
cecal bile acids levels were suppressed (Fig. 6). This suggests that
VSG directly alters the compartmental-specific bile acid pool
independently of FGF15.
Patients with NAFLD have increased hepatic Cyp7a1 levels22.
Exogenous administration of FGF19 and its analog NGM282 did
not correct hyperglycemia in diabetic patients, but caused a rapid
and sustained reduction in hepatic Cyp7a1 levels and liver fat
content in NAFLD patients22. Consistent with these observations,
we saw increased hepatic expression of Cyp7a1 in FGF15INT-KO
Sham mice compared to Control Sham (Fig. 6). However, hepatic
Cyp7a1 was significantly downregulated in FGF15INT-KO VSG
(Fig. 6). We speculate that the drastic increase in plasma bile acid
levels in FGF15INT-KO VSG mice downregulates hepatic Cyp7a1
expression as a negative feedback independent of circulating
FGF1566,67. The reduction of hepatic Cyp7a1 in FGF15INT-KO
VSG mice is VSG-dependent and FGF15-independent (unlike
observed in FGF15INT-KO Sham). As there are higher levels of
cholesterol, bile acid synthesis is facilitated because there is more
substrate. However, Cy7a1 is high in the FGF15INT-KO Sham,
because in the absence of FGF15 there is less to inhibit de novo
synthesis. But, for FGF15INT-KO VSG, the high amount of
hepatic cholesterol and decreased hepatic bile acid uptake
(decreased expression of Slc10a1 (coding for Ntcp and Oatp4),
leads to high plasma bile acids, creating negative feedback, and
as a result Cyp7a1 is downregulated in the FGF15INT-KO VSG.
Decreased hepatic Slc10a1 and Oatp4 and normal hepatic bile
acid levels suggest that the liver is actively reducing bile acid
uptake, leaving increased plasma bile acid pool. FGF15INT-KO
VSG mice have very high bile acids levels in plasma, but not in
feces. This is consistent with FGF15INT-KO VSG mice having
increased recycling of bile acids compared to FGF15INT-KO
Sham. Ileal expression of Slc10a2 (coding for Asbt) trended
higher in FGF15INT-KO VSG compared to FGF15INT-KO Sham,
which would lead to better reabsorption in the ileum, and
decreased fecal bile acids. We speculate that if the bile acid
recycling is higher in FGF15INT-KO VSG, then there is no need
to produce more bile acids, and therefore hepatic Cyp7a1
expression decreases.
Further understanding of the mechanisms that suppress
Cyp7a1 would also be useful for cancer treatments that aim to
block FGFR468. FGF15/19 signaling has been implicated in the
development of hepatocellular carcinoma, making FGFR4
antagonists attractive candidates for treating this disease68.
However, blockade of FGFR4 signaling inhibits the FGF15/19-
induced bile acid brake. The resulting elevation in hydrophobic
bile acids, as seen in FGF15INT-KO VSG mice, act as detergents
and disrupt cell membranes, and can lead to liver damage69.
Although we see significantly elevated levels of plasma bile acids
and very high levels of hydrophobic bile acids (Fig. 6 and Sup-
plementary Fig. 6) in the FGF15INT-KO VSG compared to Control
VSG mice, we do not observe signs of liver damage as noted by
normal circulating levels of ALT in FGF15INT-KO VSG mice
(Fig. 5). Our data also found that intestinal FGF15 is necessary for
the reduction in hepatic cholesterol content after VSG.
FGF15INT-KO VSG mice had increased liver weight (normalized
to body weight), despite decreased hepatic glycogen content
(Fig. 5 and Supplementary Fig. 4). Although plasma cholesterol
levels were decreased in both groups after VSG, FGF15INT-KO
VSG mice had increased hepatic total and esterified cholesterol
levels (Fig. 5). The cholesterol synthesis rate-limiting gene, Hmg-
CoA reductase (Hmcgr), was upregulated in FGF15INT-KO Sham
compared to Control Sham mice, but surprisingly reduced after
VSG in FGF15INT-KO VSG mice (Fig. 5). Hepatic cholesterol
efflux pump-ATP-binding cassette, sub-family G, members 5 and
8 (Abcg5 and Abcg8) expression was decreased in FGF15INT-KO
VSG mice (Fig. 5). These data suggest that despite decreased
cholesterol synthesis there is attenuated cholesterol export leading
to elevated liver cholesterol content in FGF15INT-KO VSG mice.
FGF21 levels were increased in FGF15INT-KO mice (especially
after VSG; Supplementary Fig. 2). FGF21 levels are tighly linked
to nutrional status, and it has been well established that FGF21
levels increase in fasting and after ketogenic and low-protein
diets70–72. The lack of FGF15, which is a postprandial hormone,
could be altering the gut-liver communication and leading to the
liver sensing a “fasting state” and increasing FGF21 levels73.
Clinical and mouse studies have reported increased plasma
FGF21 levels in patients and animal models of NAFLD74–76.
Consistent with these data, we hypothesize that plasma FGF21 is
increased in FGF15INT-KO mice as compensatory mechanism to
attenuate liver injury and hepatic lipid accumulation77. Impor-
tantly, we did not observe increased hepatic cholesterol levels in
FGF15INT-KO Sham mice compared to Control Sham (despite
increased hepatic expression of Hmcgr). It is possible that the
hepatic cholesterol in these mice is directed towards their
increased plasma bile acid levels. It is also possible that increased
FGF21 levels in FGF15INT-KO Sham were sufficient to counteract
the hepatic lipid accumulation and liver damage. Alternatively,
other tissues, including muscle and adipose tissue, could be
responsible for the increased FGF21 levels in FGF15INT-KO VSG
mice78. This is consistent with the observation that elevated
plasma FGF21 levels have been linked to decreased muscle mass50
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and reduced bone mineral density and BMAT79–81. Taken toge-
ther these observations point to the possibility that plasma FGF21
levels are not a mediator of the profound cachexia observed in
FGF15INT-KO VSG mice and are increased in response to the
muscle mass loss and/or hepatic lipid accumulation in these mice.
We did not find a difference in glucose excursion between
Control Sham and FGF15INT-KO Sham mice, suggesting that
intestinal-derived FGF15 does not play an essential role in per-
ipheral glucose tolerance, at least under HFD conditions (Fig. 4).
As expected, we saw an improvement in glucose tolerance in
Control VSG compared to Control Sham mice after intraper-
itoneal glucose challenge (ipGTT; Fig. 4). To our surprise, there
was no difference in glucose tolerance between FGF15INT-KO
VSG and FGF15INT-KO Sham mice, despite the large body weight
loss in FGF15INT-KO after VSG (Fig. 4). Loss in muscle mass as
seen in FGF15INT-KO VSG can greatly inhibit the proper disposal
of glucose, leading to glucose intolerance. However, VSG in total
body FGF15−/− mice also did not improve glucose tolerance
despite lack of change in lean tissue mass, suggesting that these
effects are FGF15-dependent and body weight-independent43. In
addition, gallbladder bile diversion to the ileum, a surgical pro-
cedure that also results in sustained weight loss and improved
glucose tolerance, is ineffective in restoring glucose tolerance in
gut-specific ablation of FXR in adult mice13. Taken together,
these data support the conclusion that the lack of improvement in
glucose tolerance in our FGF15INT-KO mice is dependent upon
the enterohepatic system. Recent studies reported that patients
who experience post-bariatric postprandial hypoglycemia have
increased postprandial levels of FGF19, linking the levels of
FGF15/19 to glucose regulation after weight-loss surgery38.
It has been reported that reduced expression of FGF15 in mice
is associated with increased gastrointestinal motility and
increased luminal water content, similar to human bile acid
diarrhea82. However, gastric emptying was lower in FGF15INT-KO
Sham compared to Control Sham mice (Fig. 4). We speculate that
the decrease in gastric emptying is a result of increased circulating
bile acids in FGF15INT-KO Sham mice, especially increased TDCA
or DCA levels83. These differences in gastric emptying rates
change after VSG. FGF15INT-KO VSG had increased gastric
emptying compared to Control VSG mice (Fig. 4). Consistent
with previous reports, we also saw an increased total GLP-1
postprandial response in Control VSG mice after a mixed meal.
The increase in total GLP-1 after VSG has been attributed to the
rapid entry of ingested glucose and nutrients into the small
intestine84. However, the GLP-1 (basal and postprandial) in
FGF15INT-KO VSG mice were much higher than Control VSG
(Fig. 4). This points to a more complicated regulation of GLP-1
secretion beyond simply nutrient presentation. Strong evidence
links bile acid activation of TGR5 to increased GLP-1
secretion85–87. Consequently, elevated levels of plasma bile
acids, such as TLCA (TGR5 agonist), in FGF15INT-KO mice given
VSG may act to increase TGR5 signaling and drive increased
GLP-1 secretion88. Interestingly, despite the elevated GLP-1
levels, FGF15INT-KO mice given VSG do not have improved
glucose tolerance pointing to a potentially more critical role of
FGF15 as compared to GLP-1.
One of the most profound and surprising findings was that
FGF15INT-KO mice lose considerably more weight than the
control mice after VSG (Fig. 1). While we have consistently
observed that mice given a VSG lose little or no lean mass48,89,
FGF15INT-KO lose 25% of their lean tissue, much more than the
control VSG mice (Fig. 1). Thus, while FGF15 does not mediate
reductions in body fat after VSG, it is essential to protect from
deleterious loss of lean mass after VSG. Loss of muscle mass is a
major concern in the setting of rapid weight loss interventions
such as very-low-calorie diets and bariatric surgery90–93.
A second component of cachexia in the FGF15INT-KO VSG
mice was due to reduced bone mass and BMAT (Fig. 2). Bar-
iatric procedures including VSG can result in bone loss beyond
the normal response to reduced loading from weight loss, or
calcium deficiency from diminished absorption52,90,94. In
FGF15INT-KO mice this effect of surgery is amplified and results
in a diffuse pattern of osseous abnormality including both
trabecular and cortical bone mass and BMAT (Fig. 2). In
humans, reduction in bone density after bariatric surgery can
predispose to fractures and is an important downside to the use
of these procedures90. It remains to be seen whether this post-
surgical metabolic bone disease can be accounted for by FGF15/
19 signaling as suggested by our findings.
The cachexia observed in FGF15INT-KO mice after VSG was
surprising and we sought to identify potential mechanisms for the
dramatic loss in muscle and bone mass in these mice. Fibroblast
growth factor 23 (FGF23), the third member of the endocrine
FGFs (in addition to FGF15/19 and FGF21), is a bone-derived
hormone that regulates mineral homeostasis and consequently
bone mineral density54,56. Plasma FGF23 levels were dramatically
elevated in FGF15INT-KO VSG mice (Fig. 3). Next, to investigate
the source of increased plasma FGF23 levels, we measured cir-
culating erythropoietin (EPO), a known driver for increased
FGF23 and bone loss55,56. Further, elevated EPO is also sufficient
to stimulate loss of bone and BMAT95. EPO was also highly
increased in FGF15INT-KO VSG mice (Fig. 3). Plasma phosphate
and 25 (OH) vitamin D levels were unaffected, as has been
reported in mice overexpressing EPO and high plasma FGF23
levels despite bone loss54. We were intrigued by these findings as
increased plasma FGF23 and EPO levels are often observed in
anemia. We have previously reported lower iron levels are
observed in bariatric surgeries with widely varying impacts on
duodenal exposure to chime, including VSG96. Hemoglobin levels
were decreased in FGF15INT-KO VSG compared to FGF15INT-KO
Sham mice, but ferritin levels were unaffected (Fig. 3). Both VSG
mice trended toward increased iron levels in cecal contents but
these were not FGF15-dependent. An increase in circulating EPO
but normal ferritin levels and near compete depletion of BMAT,
suggest that FGF15INT-KO VSG mice have bone marrow dys-
function leading to anemia of chronic disease. Our previous
studies have shown that loss of bone mass and BMAT after VSG
is inversely correlated with myeloid cell expansion in marrow52.
Therefore, the mechanism for these unexpected findings has to be
a factor dependent on both FGF15 and VSG.
FGF15INT-KO VSG mice had high levels of circulating hydro-
phobic bile acid levels (Fig. 6E, Supplementary Fig. 6). Hydro-
phobicity is an important factor for bile acid toxicity and
cholestatic injury97,98. Therefore, we hypothesize that increased
hydrophobic bile acids are an important contributor to the
cachexia seen after VSG in FGF15INT-KO mice (Fig. 8). The lack
of gut-derived FGF15 is sufficient to increase circulating total bile
acids (as can VSG), however, the combination of lack in gut
FGF15 along with VSG results in very high levels of circulating
total and most importantly, hydrophobic levels of bile acids
(Fig. 6). Increase in circulating hydrophobic bile acids can lead to
bile acid toxicity that may contribute to the cachexia observed in
FGF15INT-KO VSG mice. Further, VSG in total body FGF15−/−
mice did not lead to cachexia consistent with relatively normal
plasma levels of bile acids (compared to WT VSG)43.
Together, these data lead us to speculate that bile acids and bile
acid toxicity is a critical contributor to the muscle and bone loss
in FGF15INT-KO VSG mice (Fig. 8). Recent study showed that
antibiotic treatment and the resultant change in microbiota and
intestinal bile acids results in skeletal muscle atrophy by
decreasing bile acid-FXR-FGF15 signaling99. It has also been
reported that exogenous FGF19 induces skeletal muscle
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hypertrophy and blocks muscle atrophy induced by glucocorti-
coid treatment, sarcopenia and obesity49. The mechanism behind
these findings is not well understood, but bile acids may play a
role. We also hypothesize that dramatic increases in EPO and
FGF23 play a major role in bone density and BMAT loss in
FGF15INT-KO VSG mice. It remains unclear if and how bile acid
toxicity induces anemia of chronic disease leading to the
increase in EPO and FGF23. Further supporting the bile acid
toxicity hypothesis, FGF15INT-KO VSG mice have cardiac
hypertrophy (Fig. 3). Elevated plasma bile acids that occur in
Fig. 8 Intestinal-derived FGF15 protects against deleterious effects following sleeve gastrectomy in mice. VSG leads to an increase in ileal expression of
FGF15 and total plasma bile acids. In the absence of intestinally derived FGF15 (FGF15INT-KO), VSG leads to an even greater increase in circulating total and
specifically, hydrophobic bile acids. We speculate that the increase in hydrophobic bile acids leads to bone marrow dysfunction, which increases EPO and
FGF23 levels that likely contribute to potentially serious loss of bone mass, bone marrow adipose tissue (BMAT), inducing anemia of chronic disease.
FGF15INT-KO VSG mice have a loss of muscle mass and cardiac hypertrophy, as a result of bile acid toxicity or secondary to anemia of chronic disease.
FGF15INT-KO VSG mice also have increased hepatic cholesterol and they do not show improved glucose tolerance following VSG.
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mice with knock outs of both FXR and Shp or by pharmaco-
logical administration of the bile acids TCA and LCA also result
in cardiac hypertrophy and reduced cardiac output100,101. In
addition, anemia and increased FGF23 and EPO can also
induce cardiac hypertrophy102,103. Future studies will dissect
the effect of bile acid toxicity on the cardiovascular function of
FGF15INT-KO VSG mice, as these are important parameters for
patients undergoing bariatric surgery procedures.
The critical point from these studies is that VSG increases
circulating levels of bile acids by a mechanism that remains
unclear. Our data lead us to hypothesize that the increase in
FGF15 after VSG serves as an important break to limit this
increase so as not to become deleterious and lead to potentially
toxic levels of bile acids. In the absence of intestinally derived
FGF15, VSG leads to an even greater increase in hydrophobic bile
acids which we speculate leads to anemia of chronic disease and
increased EPO and FGF23 levels that likely contribute to great
loss of bone mass, BMAT, muscle mass, and cardiac hypertrophy.
Circulating levels of FGF19 increase in humans after VSG, but
this increase is variable between patients22,32,33,38–40. Our data
suggest that bariatric surgery patients with low FGF19 levels may
be at a higher risk for bone and skeletal muscle loss as well as
increased hepatic cholesterol accumulation.
As with many studies using the mouse to model human effects,
there are important caveats to the extrapolation to humans. Not
all aspects of the regulation of enterohepatic circulation are
identical in mouse and human and thus further work will be
needed. These experiments are time and labor intensive so we
have not directly tested whether lowering of plasma bile acids
would prevent some deleterious effects of VSG in FGF15INT-KO
mice. Future work will directly address potential therapeutic
strategies that could limit these deleterious effects of VSG. More
research is warranted to determine if circulating FGF19 can act as
a biomarker to identify patients that are at high risk for excessive
bile acid levels and these negative outcomes following bariatric
surgery. Understanding this relationship would allow physicians
to optimize treatment strategies for at risk patients.
Methods
Study approval. All protocols complied with all relevant ethical regulations for
animal testing and research. All protocols were approved by the University of
Michigan (Ann Arbor, MI) Animal Care and Use Committees and were in
accordance to NIH guidelines.
Generation of FGF15 flox mouse. Gene sequence for the mouse FGF15 gene (4.4k
base pair double strands DNA containing fgf15 exon) was downloaded from
genebank. Guide RNAs were designed against the mouse sequence containing the
region of interest for targeting (introns flanking FGF15 exon 2) using prediction
algorithms available through http://crispor.tefor.net/. Guides were selected based
on the specificity score and predicted efficiency (Mor.Mateos). Selected single guide
RNA (sgRNA) sequences were subcloned into plasmid pX330 and subsequently
confirmed by sequencing. Targeting DNA oligonucleotides including the 34 base
pairs loxP site and 81-82 nucleotides of flanking sequence on either side were
generated (IDT Technologies). DNA oligonucleotides were designed to disrupt the
sgRNA and PAM sequences so that Cas9 would not be able to cleave the inserted
sequence after incorporation into the genome. To test the ability of the sgRNAs to
cut chromosomal DNA appropriately, each sgRNA was injected into fertilized eggs
by the University of Michigan Transgenic Animal Core; zygotes were then allowed
to develop into blastocysts in culture. PCR amplification of the target region fol-
lowed by sequencing was used to confirm Cas9 dependent DNA cutting in vivo.
Cas9/sgRNA/oligo donor were then injected into 300 fertilized mouse eggs
(C57BL/6x SJL) and transferred to pseudo-pregnant recipients for gestation. After
delivery of potential founders, tail DNA was isolated and screened by PCR across
the region of interest to identify genomic manipulations. As founders are often
mosaic for allelic changes, PCR products of genomic DNA were subcloned into
topo vector and sequenced to characterize the genetic modification in the mice.
Animals and diet. The FGF15 flox/flox mice, were built using CRISPR-Cas9
technology with LoxP sites flanking exon 2 of the FGF15 gene (described above).
We bred these mice to VilCreERT2 mice (C57BL background) and administered
tamoxifen (intraperitoneal, 3 doses/150 mg/kg) to VilCreERT2; Fgf15flox/flox and
controls (VilCreERT2 and Fgf15 flox/flox). We validated exon 2 excision within the
latter jejunal and ileal mucosa, where FGF15 is most highly expressed (Supple-
mentary Fig. 1). Male mice (6–8 weeks of age) were single-housed under a 12-h
light/dark cycle with ad libitum access to water and food. A week after tamoxifen
administration, FGF15INT-KO and Control male mice (all littermates) were placed
on 60% HFD from Research Diets, Inc. (New Jersey, US; Catalog D12492) for
8 weeks. Mice were singly-housed under a 12-h light/dark cycle in a facility
maintained at 25 °C with 50–60% humidity for the duration of the studies. Mice
underwent VSG or Sham surgery (described below) and returned to 60% HFD four
days after surgery until the end of the study.
Animals were euthanized 12 weeks post-surgery (26-28 weeks of age). One
Control Sham mouse died accidentally during NMR measurements on the day
before necropsy. The post-necropsy data on metabolites and tissue gene expression
for this Control Sham mouse was excluded, but the data not sensitive to nutritional
state was included. The rest of the mice were fasted overnight, administered oral
mixed meal (volume 200 µl Ensure Plus spiked with a 40-mg dextrose), and
sacrificed 90 min later. Plasma and tissues were collected and frozen immediately.
All animals were euthanized using CO2.
VSG in mice. Mice were maintained on a 60% HFD for 8 weeks prior to under-
going Sham or VSG surgery48,104,105. Mice were fasted overnight prior to day of
surgery. Animals were anesthetized using isoflurane, and a small laparotomy
incision was made in the abdominal wall. The lateral 80% of the stomach along the
greater curvature and fundus was excised in VSG animals by using an Echelon
FlexTM powered vascular stapler (Ethicon Endo-Surgery, USA). The Sham surgery
was performed by the application of gentle pressure on the stomach with blunt
forceps for 15 seconds. All mice received one dose of Buprinex (0.1 mg/kg) and
Meloxicam (0.5 mg/kg) immediately after surgery. All mice received Meloxicam
(0.5 mg/kg) for 3 days after surgery and Enrofloxacin (40 mg/kg) for 5 days after
surgery. Animals were placed on DietGel Boost (ClearH2O; Postland ME) for
3 days after surgery. They were placed back on pre-operative solid diet (60% HFD)
on day 4 post-surgery. Body weight and food intake as well as overall health were
monitored daily for the first 7 days after surgery and once weekly until end of the
studies.
Metabolic studies. Body weight was monitored monthly for 9 weeks prior and
12 weeks after Sham/VSG surgery. Intraperitoneal glucose tolerance test (IPGTT)
was performed by intraperitoneal (IP) injection of 50% dextrose (2 g/kg) in 4-h
fasted mice. Mixed-meal tolerance test (MMTT) was performed via an oral gavage
of liquid meal (volume 200 µl Ensure Plus spiked with a 40-mg dextrose and 4-mg
acetaminophen, Sigma-Aldrich) in 4-hour fasted mice. Blood was obtained from
the tail vein and blood glucose was measured with Accu-Chek blood glucose meter
(Accu-Chek Aviva Plus, Roche Diagnostics). Blood was collected from the tail vein
at baseline and 15 min after gavage in EDTA-coated microtubes. Plasma acet-
aminophen levels were used to assess the rate of gastric emptying and were
measured using spectrophotometry assay (Sekisui Diagnostics).
ELISA and metabolite assays. Insulin (Crystal Chem), total GLP-1 (MesoScale
Discovery), and acetaminophen (Sekisui Diagnostics) were measured during
experiments shown in Fig. 3. Insufficient amount of blood was obtained from one
Control VSG for insulin, total GLP-1 and acetaminophen levels at 15 min. Post-
prandial plasma obtained at termination of studies (see above for details) was used
to measure IGF-1 (R&D Systems), Activin-A (R&D Systems), Myostatin (GDF8)
(R&D Systems), FGF21 (R&D Systems), L-amino acids (Abcam), Erythropoietin
(Abcam), FGF23 (Abcam), Ferritin (Abcam), Hemoglobin (Abcam), Phosphate
(Abcam), 25(OH) Vitamin D (Abcam). Iron levels in cecal contents were measured
with Iron Assay Kit (Abcam). Glycogen content was measured in liver and muscle
(tibialis anterior) samples with Glycogen Assay kit (Sigma-Aldrich). All sampled
blood was collected via tail vein in EDTA-coated tubes. All assays were performed
according to the manufacturer’s instructions.
Plasma bile acid composition. Plasma bile acid composition was measured by the
University of Michigan Metabolomics Core using two-step solvent extraction.
Supernatants are combined, dried, and re-suspended for LCMS separation by
RPLC and measurements by ESI- QQQ MRM methods106. Sample preparation:
20 µL plasma was transferred to a microtube. Eighty microliters of chilled acet-
onitrile with 5% NH4OH, containing isotope-labeled internal standards was added
to the tube, and the mixture vortexed until completely homogenized. The mixture
was incubated on ice for 10 min and vortexed to remix. This homogenized mixture
was centrifuged and 3 µL of the supernatant from each sample was removed to
create a pooled sample for QC purposes. Next, 90 µL of the supernatant transferred
to an LC-MS autosampler insert and brought to dryness in a speedvac set to 45 °C
for ~45 min. Each sample was reconstituted in 100 µL of 50/50 Methanol/Water.
A series of calibration standards ranging from 0 to 1000 nM were prepared along
with samples to quantify metabolites. LC-MS analysis: LC-MS analysis was per-
formed on an Agilent system consisting of a 1290 UPLC module coupled with a
6490 Triple Quad (QqQ) mass spectrometer (Agilent Technologies, Santa Clara,
CA) operated in MRM mode. MRM transitions are included in the table below.
Metabolites were separated on a 100 mm × 2.1 mm Acquity BEH UPLC (1.7 µm)
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column (Waters Corp, Milford, MA) using H2O, 0.1% Formic acid, as mobile
phase A, and Acetonitrile, 0.1% Formic acid, as mobile phase B. The flow rate was
0.25 mL/min with the following gradient: linear from 5 to 25% B over 2 min, linear
from 25 to 40% B over 14 min, linear from 40 to 95% B over 2 min, followed by
isocratic elution at 95% B for 5 min. The system was returned to starting conditions
(5% B) in 0.1 min and held there for 3 min to allow for column re-equilibration
before injecting another sample. The mass spectrometer was operated in ESI- mode
according to previously published conditions. Data were processed using Mas-
sHunter Quantitative analysis version B.07.00. Metabolites were normalized to the
nearest isotope-labeled internal standard and quantitated using two replicated
injections of five standards to create a linear calibration curve with accuracy better
than 80% for each standard. Using ROUT method and treating all the values in all
subgroups as one set of data (Q= 1), we identified three samples (one Control VSG
and two FGF15INT-KO Sham) as significant outliers. QQ plot and Homoscedasticity
plot showed that these samples were out of the normal distribution. In addition,
analysis of total bile acids in the same samples using Total Bile Assay (NBT
Method) (GenWay Biotech Inc; San Diego, CA) also revealed that these samples
are abnormally elevated. Therefore, these samples were excluded from all plasma
bile acid data analysis. Plasma bile acid composition data are available at the NIH
Common Fund’s National Metabolomics Data Repository (NMDR) website, the
Metabolomics Workbench, https://www.metabolomicsworkbench.org where it has
been assigned Project ID (PR001116). The data can be accessed directly via it’s
Project DOI: (10.21228/M8FM51).
Lipid and bile acid measurements in tissues. Liver and cecal content lipids were
extracted using Lipid Extraction Kit Chloroform Free (Abcam). Total and cho-
lesterol ester (Millipore/Sigma-Aldrich), triglycerides (Abcam), free fatty acids
(Abcam), and total bile acids (Total Bile Assay (NBT Method), GenWay Biotech
Inc; San Diego, CA) were measured using the extracted liver lipids. Cecal content
total bile acids were measured using the extracted cecal content lipids (Total Bile
Assay (NBT Method) assay, GenWay Biotech Inc; San Diego, CA). Postprandial
plasma obtained at termination of studies (see above for details) was used to
measure total cholesterol (Pointe Scientific), triglycerides (Pointe Scientific), free
fatty acids (Abcam), ALT (Pointe Scientific). All assays were performed according
to the manufacturer’s instructions.
Bone parameters. Tissues were fixed in 10% neutral-buffered formalin for 24 h
and kept in Sorenson’s buffer (pH7.4) thereafter. Tibiae were placed in a 19-mm
diameter specimen holder and scanned over the entire length of the tibiae using a
microcomputed tomography (μCT) system (μCT100 Scanco Medical). Scan set-
tings were as follows: voxel size 12 μm, 70 kVp, 114 μA, 0.5 mm AL filter, and
integration time 500 ms. Density measurements were calibrated to the manu-
facturer’s hydroxyapatite phantom. Analysis was performed using the manu-
facturer’s evaluation software and a threshold of 180 for trabecular bone and 280
for cortical bone. Tibiae used for μCT scanning were decalcified in 14% EDTA for
3 weeks. Paraffin-embedded tissue sections were processed and stained with H&E.
Bone Marrow Adipose Tissue Quantification by Osmium Tetroxide Staining
and μCT: Mouse tibiae were decalcified in 14% EDTA for 2-3 weeks, and then put
into 1% osmium tetroxide solution (diluted by Sorenson’s buffer pH7.4) for 48 h.
Osmium tetroxide-stained bones were scanned by the same program as described
above. A threshold of 400 Gy was used for BMAT quantification. The volume of
BMAT was normalized by the total volume (TV) of bone and shown as
percentage (%).
Muscle fiber area and ileal crypt depth/villi height analysis. Soleus muscle and
ileal section were dissected and fixed in 10% neutral-buffered formalin overnight.
Tissue was embedded in paraffin and sectioned onto slides and stained for H&E
following standard protocol. Photos, and analysis of muscle fiber area (in 100–250
muscle fibers), and ileal crypt depth, and ileal villi height (in 25 villi and crypts)
were acquired using Olympus IX73 fluorescence microscopy system (Olympus).
Villus height was measured from the crypt-villus junction to the tip of the villus
and crypt depth was measured from the base of the crypt to the crypt-villus
junction. Images were analyzed using Olympus cellSens Standard imaging software
(Olympus).
Grip strength. Grip strength was measured with Columbus Instruments Grip
Strength Meter (Colombus Instruments), which assesses neuromuscular function
by sensing the peak amount of force an animal applies in grasping specially
designed pull bar assemblies. Metering was performed with precision force gauges
in such a manner as to retain the peak force applied on a digital display. The dual
sensor model was employed by first allowing the animal to grasp the forelimb pull
bar assembly. The animal was then drawn along a straight line leading away from
the sensor. The animal released at some point and the maximum force attained is
stored on the display. Each animal was tested five times and the average force
reported in the data. Grip strength test was performed by the University of
Michigan Physiology Phenotyping Core.
Absorbed energy content. Fecal energy was assessed by the University of
Michigan Animal Phenotyping core using Bomb Calorimeter, Parr 6200, and
1108P oxygen bomb107. Mice were single-housed in clean housing cages for one
week. Food weight was determined for the same time period. All fecal samples are
collected using forceps and weighed to determine “wet weight”. Prior to processing,
fecal samples are dried overnight at 50 °C. Samples are then removed from the oven
one at a time and weighed. Sample weights are recorded and fecal samples are then
ground-up individually. Samples are ground with mortar and pestle and carefully
scooped into a dry tube. All instruments were washed with sparkleen and 10%
bleach and completely dried between samples. New weigh boats are used for each
sample and weighed on the same scale as the pre-dried weights.
Quantitative real-time PCR. RNA was extracted from tissue samples using
RNeasy isolation kit (Qiagen). cDNA was synthesized by reverse transcription from
mRNA using the iScript cDNA Synthesis Kit (Bio-Rad). Gene expression was
performed by quantitative real-time RT-PCR using Taqman gene expression assay
(Supplementary Table 1) and was performed using StepOnePlus detection system
(Applied Biosystems) with a standard protocol. Relative abundance for each
transcript was calculated by a standard curve of cycle thresholds and normalized to
RL32. One Control VSG ileum sample was excluded due to the high cycle threshold
of RL32 (Ct over 30 after two independent measurements).
Intestinal biometry. Following euthanasia, the entire gastrointestinal tract from
the stomach to the rectum was removed, cleaned of mesenteric fat and gut weight
and length determined. Small and large intestine/colon length was measured on a
horizontal ruler after flushing with PBS. The entire small and large intestine/colon
were then blotted to remove PBS before being weighed.
Analysis of 16S rRNA Gene Sequences. 16S rRNA Sequencing: Cecal contents
were added to individual Bead plate provided by the Microbiome Core at the
University of Michigan. DNA was isolated using Qiagen MagAttract Power-
Microbiome kit DNA/RNA kit (Qiagen, catalog no. 27500-4-EP) on the EpMotion
5075 (Eppendorf) liquid handler. Extracted DNA was then used to generate 16S
rRNA libraries for community analysis. The DNA libraries were prepared by the
Microbiome Core as described previously108. Briefly, DNA was PCR amplified
using a set of barcoded dual-index primers specific to the V4 region of the 16S
rRNA gene109. PCR reactions are composed of 5 µL of 4 µM equimolar primer set,
0.15 µL of AccuPrime Taq DNA High Fidelity Polymerase, 2 µL of 10x AccuPrime
PCR Buffer II (Thermo Fisher Scientific, catalog no.12346094), 11.85 µL of PCR-
grade water, and 1 µL of DNA template. The PCR conditions used consisted of
2 min at 95 °C, followed by 30 cycles of 95 °C for 20 s, 55 °C for 15 s, and 72 °C for
5 min, followed by 72 °C for 10 min. Each PCR reaction is normalized using the
SequalPrep Normalization Plate Kit (Thermo Fisher Scientific, catalog no.
A1051001). The normalized reactions are pooled and quantified using the Kapa
Biosystems Library qPCR MasterMix (ROX Low) Quantification kit for Illumina
platforms (catalog no. KK4873). The Agilent Bioanalyzer is used to confirm the size
of the amplicon library (~399 bp) using a high-sensitive DNA analysis kit (catalog
no. 5067-4626). Pooled amplicon library is then sequenced on the Illumina MiSeq
platform using the 500 cycle MiSeq V2 Reagent kit (catalog no. MS-102-2003)
according to the manufacturer’s instructions with modifications of the primer set
with custom read 1/read 2 and index primers added to the reagent cartridge. The
“Preparing Libraries for Sequencing on the MiSeq” (part 15039740, Rev. D) pro-
tocol was used to prepare libraries with a final load concentration of 5.5 pM, spiked
with 15% PhiX to create diversity within the run. FASTQ files are generated when
the 2 × 250 bp sequencing completes. Analysis: Following sequencing, microbiome
bioinformatics were run using QIIME 2 2020.2110. Briefly, non-singleton amplicon
sequence variants (ASVs, 100% operational taxonomic units (OTUs)) were gen-
erated from raw sequences after trimming with the cutadapt plugin denoising with
the dada2 plugin. One Control VSG and one FGF15INT-KO Sham samples were
excluded because of low OTUs. Taxonomy was then assigned to ASVs using the
classify-sklearn alignment algorithm (Bokulich et al.111) against the Greengenes
database (Release 13.8) of 99% OTUs reference sequences (McDonald et al.112).
Alpha diversity metrics including Chao1 and Shannon, which estimate with-in
sample richness and diversity respectively, were calculated using the diversity
plugin. Chao1 index represents the number of ASVs present in one single sample,
while Shannon index accounts for both abundance and evenness of ASVs present.
Beta diversity metrics including weighted and unweighted UniFrac distance
matrix113, which estimate between-sample dissimilarity, were scaled and visualized
through principal coordinates analysis (PCoA), and further used to determine the
significance of the clustering between groups via permutational multivariate ana-
lysis of variance (PERMANOVA). Linear discriminant analysis (LDA) effect size
(LEfSe) with default parameters114 and Random Forest Classifier (QIIME 2 2020.2)
with 10-fold cross-validations115 were computed to identify significantly
different microbes in abundance between groups at different taxonomic levels.
The 16S rRNA Sequencing composition data generated in this study have been
deposited in the Sequence Read Archive (SRA) where it has been assigned Bio-
Project ID PRJNA734599. The data can be accessed directly via it’s Project URL:
http://www.ncbi.nlm.nih.gov/bioproject/734599.
Statistics and reproducibility. The researchers were blinded during studies and
mouse order (per genotype and surgery) were randomized. Microcomputed
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tomography (μCT) analysis for bone parameters and bone marrow adiposity were
completed by two independent experienced lab researchers in a blinded manner.
Bone histology images were taken from each individual mouse and all images were
quantified. Representative images of the mean number based on the quantification
were shown in Fig. 2. Liver histology images were taken from each individual
mouse and representative images were shown in Fig. 3. All metabolic studies were
performed at least twice with the same results and data were shown over multiple
time points (body weight, body composition, food intake, glucose tolerance). All
studies were performed in a sufficient number of biological replicates per genotype
and surgery.
Statistical analysis. The statistical analysis for comparisons between two groups
was performed by unpaired (two-tailed) Student’s t test. Two-way ANOVA with
post hoc Tukey’s multiple comparisons post hoc test was used for comparisons
among four groups. P values <0.05 were considered significant. Statistical analysis
was performed using GraphPad Prism 8.2.0. Microbiome analysis is
described above.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Plasma bile acid composition data generated in this study have been deposited in the
NIH Common Fund’s National Metabolomics Data Repository (NMDR) website, the
Metabolomics Workbench, https://www.metabolomicsworkbench.org where it has been
assigned Project ID (PR001116). The data can be accessed directly via it’s Project DOI:
(10.21228/M8FM51). The 16S rRNA Sequencing composition data generated in this
study have been deposited in the Sequence Read Archive (SRA) where it has been
assigned BioProject ID PRJNA734599. The data can be accessed directly via it’s Project
URL: http://www.ncbi.nlm.nih.gov/bioproject/734599. The authors declare that the data
supporting the findings of this study are available within the paper and its supplementary
information files. Source data are provided with this paper.
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